Research programme: hydroxysteroid dehydrogenase inhibitors - Amgen

Drug Profile

Research programme: hydroxysteroid dehydrogenase inhibitors - Amgen

Alternative Names: 11β-HSD1 inhibitors - Amgen

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator Biovitrum
  • Developer Amgen
  • Class Nitriles; Small molecules; Thiazoles
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 22 Feb 2010 Preclinical development is ongoing in Sweden and USA
  • 14 Jan 2010 Biovitrum has combined with Swedish Orphan forming Swedish Orphan Biovitrum
  • 21 Aug 2008 Preclinical pharmacokinetics data presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top